Retrospective analysis shows daratumumab enhances renal function and hematologic response in patients with monoclonal immunoglobulin deposition disease, suggesting better outcomes.
Key Points
Evaluate the impact of daratumumab on renal and hematologic responses in patients with monoclonal immunoglobulin deposition disease.
Multi-center retrospective analysis of patients diagnosed with monoclonal immunoglobulin deposition disease at three academic medical centers.
Data collected included demographics, organ involvement, renal function, and therapies used for treatment.
Patients were divided into groups based on daratumumab use to compare outcomes.
Renal response improved significantly in the daratumumab group (77% vs 40%, P=0.04).
Median follow-up of 27 months showed lower progression to ESRD in the daratumumab group (10% vs 40%, P=0.04).
Overall hematologic response rates were comparable between groups (90% vs 75%, P=0.31).